We discuss a case where medically optimal investigations of health problems in a donor-conceived child would require their egg donor to participate in genetic testing. We argue that it would be justified to contact the egg donor to ask whether she would consider this, despite her indicating on a historical consent form that she did not wish to take part in future research and that she did not wish to be informed if she was found to be a carrier of a 'harmful inherited condition'. We suggest that we cannot conjecture what her current answer might be if, by participating in clinical genetic testing, she might help reach a diagnosis for the donor-conceived child. At the point that she made choices regarding future contact, it was not yet evident that the interests of the donor-conceived child might be compromised by her answers, as it was not foreseen that the egg donor's genome might one day have the potential to enable diagnosis for this child. Fertility consent forms tend to be conceptualised as representing incontrovertible historical boundaries, but we argue that rapid evolution in genomic practice means that consent in such cases is better seen as an ongoing and dynamic process. It cannot be possible to compel the donor to aid in the diagnosis of the donor-conceived child, but she should be given the opportunity to do so.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613744 | PMC |
| http://dx.doi.org/10.1136/medethics-2018-105322 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The State of Surrogacy in New York: A New National Prototype, New Patrons, New Perils?
J Med Humanit
December 2024
Columbia University, New York, NY, USA.
Article Synopsis
- The text discusses the evolution of the infertility industry in New York since the Baby M case, highlighting the rise of gestational carrier pregnancies and compensated surrogacy in various states due to advanced reproductive technologies.
- It notes that the USA has become a popular destination for international couples seeking surrogacy, driven by strong medical care, available gestational carriers, and citizenship benefits for children born through these arrangements.
- The author critiques the Child-Parent Security Act of 2021, pointing out the lack of strong regulations that protect gestational carriers and donor-conceived offspring, raising concerns about health risks, informed consent, and the market-driven nature of compensated surrogacy.
Adopted and donor-conceived children hold reduced genetic-essentialist beliefs relative to traditionally-conceived children.
Dev Psychol
October 2024
Mailman School of Public Health, Columbia University.
For three decades, researchers have assessed children's genetic essentialism through an "Adoption Task," probing their beliefs about whether adopted babies grow up to resemble their birthparents or adoptive parents. The present study investigates these beliefs among children who were themselves adopted or donor-conceived (i.e.
View Article and Find Full Text PDFDiagnosing a genetic disease in a donor-conceived child: case report and discussion of the ethical, legal, and practical issues.
Pediatr Nephrol
October 2024
Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, M5G 1X8, Canada.
We describe the unexpected challenges pediatricians may experience when children conceived with assisted reproduction are diagnosed with a rare genetic condition. A local case series triggered a dialogue between many stakeholders with varied expertise. Indeed, diagnosing a genetic disease in a child conceived by embryo, egg, or sperm donation is becoming more common now that genetic testing and in vitro fertilization (IVF) are readily accessible.
View Article and Find Full Text PDFSurvey on ART and IUI: legislation, regulation, funding, and registries in European countries-an update.
Hum Reprod
September 2024
ESHRECentral Office, Grimbergen, Belgium.
Study Question: How are ART and IUI regulated, funded, and registered in European countries, and how has the situation changed since 2018?
Summary Answer: Of the 43 countries performing ART and IUI in Europe, and participating in the survey, specific legislation exists in only 39 countries, public funding varies across and sometimes within countries (and is lacking or minimal in four countries), and national registries are in place in 33 countries; only a small number of changes were identified, most of them in the direction of improving accessibility, through increased public financial support and/or opening access to additional subgroups.
What Is Known Already: The annual reports of the European IVF-Monitoring Consortium (EIM) clearly show the existence of different approaches across Europe regarding accessibility to and efficacy of ART and IUI treatments. In a previous survey, some coherent information was gathered about how those techniques were regulated, funded, and registered in European countries, showing that diversity is the paradigm in this medical field.
Introduction: Parents who use donated gametes or embryos to form their families struggle with telling their children about their genetic origins. We developed the Tool to Empower Parental Telling and Talking (TELL Tool) to support parents in disclosure to their children and an eBook attention control.
Method: A randomized parallel, two-group, attention-controlled clinical pilot trial was conducted online during COVID-19.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!